Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2003-04-16
2010-10-12
Azpuru, Carlos A (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
Reexamination Certificate
active
07811606
ABSTRACT:
Nasal pharmaceutical formulations comprising a drug substance having a specific particle size distribution profile are disclosed herein. Such profile provides increased bioavailability, increased efficacy or prolonged therapeutic effect of the drug substance when administered intranasally. The formulations of the present invention may comprise one or more corticosteroids having a specific particle size distribution profile. In a preferred embodiment, the corticosteroid is beclomethasone or a pharmaceutically acceptable derivative thereof for the treatment of one or more symptoms of rhinitis. Preferably, the drug substance is beclomethasone dipropionate. The formulations herein may be provided as an aqueous suspension suitable for inhalation via the intranasal route.
REFERENCES:
patent: 3091569 (1963-05-01), Sheffner
patent: 5174475 (1992-12-01), Day et al.
patent: 5593688 (1997-01-01), Baldeschwieler
patent: 5858330 (1999-01-01), Boltri et al.
patent: 5976573 (1999-11-01), Kim
patent: 5993781 (1999-11-01), Snell et al.
patent: 6113894 (2000-09-01), Smith
patent: 6207703 (2001-03-01), Ponikau
patent: 6241969 (2001-06-01), Saidi et al.
patent: 6291500 (2001-09-01), Ponikau
patent: 6368616 (2002-04-01), Doi
patent: 6410062 (2002-06-01), Callaghan et al.
patent: 6464958 (2002-10-01), Bernini et al.
patent: 6465709 (2002-10-01), Sun et al.
patent: 6509028 (2003-01-01), Williams et al.
patent: 6555566 (2003-04-01), Ponikau
patent: 6608054 (2003-08-01), Meade et al.
patent: 2001/0002404 (2001-05-01), Webb et al.
patent: 2002/0006944 (2002-01-01), Ohkawa et al.
patent: 2002/0010208 (2002-01-01), Shashoua et al.
patent: 2002/0013331 (2002-01-01), Williams et al.
patent: 2002/0052390 (2002-05-01), Ponikau
patent: 2002/0061281 (2002-05-01), Osbakken et al.
patent: 2002/0071874 (2002-06-01), Olejnik et al.
patent: 2002/0124820 (2002-09-01), Kreuter
patent: 2002/0136918 (2002-09-01), Akutsu et al.
patent: 2002/0177609 (2002-11-01), Swindell et al.
patent: 2002/0192288 (2002-12-01), Williams et al.
patent: 2002/0198209 (2002-12-01), Woodward et al.
patent: 2003/0017199 (2003-01-01), Woodward et al.
patent: 2003/0065023 (2003-04-01), Swindell et al.
patent: 2004/0045805 (2004-03-01), Lancaster et al.
patent: 2004/0081626 (2004-04-01), Watanabe et al.
patent: 2004/0136918 (2004-07-01), Garrett et al.
patent: 2004/0141925 (2004-07-01), Bosch et al.
patent: 2007/0140980 (2007-06-01), Capocchi et al.
patent: 2008/0050442 (2008-02-01), Chaudry
patent: 0 343 268 (1989-11-01), None
patent: WO86/03750 (1986-03-01), None
patent: WO 92/04365 (1992-08-01), None
patent: WO 92/17183 (1992-10-01), None
patent: WO 99/18971 (1999-04-01), None
patent: WO 00/25746 (2000-05-01), None
patent: WO 00/27363 (2000-05-01), None
patent: WO 01/32125 (2001-05-01), None
patent: WO 01/49263 (2001-07-01), None
patent: WO 02/00199 (2002-01-01), None
Drug Information Handbook, C. Lacy et al., Lexi-Comp, Inc., Cleveland, 1993, pp. 397.
The Diagnosis and Incidence of Allergic Fungal Sinusitis - Jens U. Ponikau, MD; David A. Sherris, MD; Eugene B. Kern, MD; Henry A. Homburger, MD; Evangelos Frigas, MD; Thomas A. Gaffey, MD; and Glenn D. Robers, PhD—1999 Mayo Foundation for Medical Education and Research—May Clin. Proc, Sep. 1999, vol. 74.
Mayo Clinic, Rochester, Minnesota—Mayo Clinic Receives Patent for New Treatment of Chronic Sinus Infection Apr. 30, 2003—http://www.mayclinic.org
ews2003-rst/1772.html.
NCBI—PubMed—Improved method for estimation of azole antifungal inhibitory concentrations against Candida Species, based on azole/antibiotic interactions; Odds FC, Abbot AB, Pye G., Troke PF.; Mar. 17, 2003.
Invasive aspergillus rhinosinusitis in patients with acute leukemia (Mar.-Apr. 13, 1991) http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd—Retrieve&db=PubMed&List—uids-19.
Efficacy of Sch39304 in murine cyptococcosis (Aug. 1989) http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd—Retrieve&db=PubMed&List—uids-25.
Lacy, C. et al., 1999-2000 Drug Information Handbook, Lexi-Comp, Inc., Cleveland, 1999, pp. 112-114.
Lacy, C. et al., Drug Information Handbook, Lexi-Comp, Inc., Cleveland, 1999, pp. 445-446.
FLONASE® from the online Physician's Desk Reference (PDR®)-accessed Dec. 1, 2007.
“BECONASE AQ®” from the online Physician's Desk Reference (PDR®)-accessed Nov. 19, 2007.
Chervinsky, P., “Clinical Review of Once-Daily Beclomethasone Dipropionate for Seasonal Allergic Rhinitis”, Clinical Therapeutics, 1996, 18(5), pp. 790-796.
Lacy et al., 1999-2000 Drug Information Handbook, Lexi-Comp, Inc., Aug. 21, 1999, 26-28, 2.
Walker, Management of Allergic Rhinitis, Nursing Times, Aug. 21, 2003, 99(23).
Humuy et al., Topical Antiviral Agents for Herpes Simplex Virus Infections, Drugs Today, Aug. 21, 1998, 34(12).
Vippagunta et al., Crystalline Solids, Advanced Drug Delivery Reviews, Aug. 21, 2001, 3-26, 48.
Lacy et al., 1999-2000 Drug Information Handbook, Lexi-Comp, Inc., 1999, pp. 561-563 and 568-569.
Hebrecht et al., “Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis”, N.Eng. J. Med., 2002, 347(6), pp. 408-415.
Bernstein, I. L.,Is the Use of Benzalkonium Chloride as a Preservative for Nasal Formulations a Safety Concern? A Cautionary Note Based on Compromised Mucociliary Transport, J. Allergy Clin. Immunol., 105(1), Jan. 2000, pp. 39-44.
Office Action dated Jul. 12, 2010, and issued in connection with corresponding Canadian Application No. 2,522,294 (Our Ref: 340938).
Office Action mailed Aug. 6, 2010, and issued in connection with corresponding U.S. Appl. No. 10/657,550 (Our Ref: 277062).
Parikh, A., et al.; Topical corticosteroids in chronic rhinosinusitis: a randomized, double-blind, placebo-controlled trial using fluticasone propionate aqueous nasal spray; Rhinology, 39; 2001; pp. 75-79.
Alston & Bird LLP
Azpuru Carlos A
Dey L.P.
LandOfFree
Nasal pharmaceutical formulations and methods of using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nasal pharmaceutical formulations and methods of using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nasal pharmaceutical formulations and methods of using the same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4153559